Texas Tech researchers also hold the exclusive license for HemoTech, a human blood substitute composed of bovine hemoglobin. HemoBioTech, the company marketing the technology, believes that HemoTech will diminish the intrinsic toxicities that have stifled previous attempts to develop a human blood ...
Texas Tech researchers also hold the exclusive license for HemoTech, a human blood substitute composed of bovine hemoglobin. HemoBioTech, the company marketing the technology, believes that HemoTech will diminish the intrinsic toxicities that have stifled previous attempts to develop a human blood ...